introduction Glioblastoma is the most frequent and most aggressive primary brain tumor in adults [1] . The combined radio-and chemotherapy (RT plus CT) has become the standard of care [2] and has substantially improved the prognosis, particularly for tumors exhibiting a methylated promoter of the gene encoding O 6 -methylguanine-DNA methyltransferase (MGMT) [3] . Gross total resection (GTR) before adjuvant treatment has also been shown to gain a favorable impact on outcome [4] [5] [6] . In contrast, the prognostic place of incomplete resection when compared with biopsy only is not yet clearly defined [2] . The elucidation of this question is important since GTR cannot be always achieved [7, 8] .
This multicenter observational study was conducted to identify prognostic factors in glioblastoma patients treated according to current standards of care. Based on our previous analysis on nonresectable glioblastomas demonstrating surprisingly long survival after biopsy only in the era of RT plus CT [9] , we awaited similar survival rates after incomplete resection and biopsy only.
patients and methods

study design
The German Glioma Network (GGN) has generated a prospective longitudinal database to follow patients with newly diagnosed glioblastoma. Patients were recruited from October 2004 until March 2009; database closure was March 2012. All patients gave informed consent. Data collection at enrolment and follow-up addressed important patient-, tumor-, and treatment-related parameters, including MGMT promoter methylation status. The extent of open resection (EOR) was determined locally by early (<72 h) postoperative magnetic resonance imaging (MRI) and scored according to the study of Stummer et al. [10] either as GTR (no residual contrast enhancement in T 1 -weighted sequences) or incomplete resection (any contrast enhancement with a volume of more than one voxel in the T 1 -weighted images). Prospective estimations of EOR were done in a blinded fashion. No additional volumetric analyses were carried out. Central histological review, according to the World Health Organization (WHO) [1] , was done at the Department of Neuropathology, University of Bonn. Central determination of the MGMT promoter methylation status by methylationspecific PCR [3] was carried out at the Department of Neuropathology, Heinrich Heine University Düsseldorf. Data were centrally collected and analyzed [Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig]. Treatment decisions were independently rendered at each academic center. Tumor progression was assessed according to the Macdonald criteria [11] .
statistical analysis
Associations of clinical data were tested by the χ 2 test, Fisher's exact test, and
Mann-Whitney U-test. Survival data were analyzed with the Kaplan-Meier method. A reference point was the date of first surgery. The log-rank test was used to compare outcome data. Multivariate analyses were carried out with Cox regression models. P-values of ≤0.05 were considered as statistically significant. Statistical analyses were carried out using IBM SPSS (Version 20.0.0).
results
A total of 345 patients were analyzed. Clinical data of the study population are summarized in Table 1 . Sixty-two patients were older than 70 years and 28 had a Karnofsky performance score (KPS) of <70. GTR, incomplete resection, and biopsy were done in 125 patients, 148, and 72, respectively. Biopsied patients were older (median: 65 versus 60 years; P = 0.008), rated similarly on the performance scale (median KPS: 80 each, P = 0.5), and had similarly often an eloquent tumor location (23.6% versus 19.4%; P = 0.4) when compared with those undergoing incomplete resection. The frequency of an eloquent tumor location was lowest in the GTR group (14.4%; P = 0.04). Transient complication occurred in 33 patients after resection and in 1 patient after biopsy (P = 0.007). Histopathological diagnosis revealed 329 glioblastomas, 9 giant cell glioblastomas, and 7 gliosarcomas. A methylated MGMT promoter was found in 48.1% of the study cohort. Methylated and unmethylated tumors did not differ in terms of age (median: 60 versus 62 years; P = 0.4), KPS (median: 80 each, P = 0.3), EOR (P = 0.8), or mode of first-line treatment (P = 0.8).
64.3% of the study population patients underwent RT plus CT. RT alone, CT alone, and supportive treatment were applied in 20.0%, 4.3%, and 11.3%, respectively. Patients ≤60 years (odds ratio 3.3, 95% CI 2.1-5.3) and those with KPS of ≥90 (odds ratio 3.0, 95% CI 1.8-4.8) were more likely to receive RT plus CT. Biopsied patients were less frequently treated with RT plus CT (odds ratio 0.5, 95% CI 0.3-0.8) and received more often supportive care only (odds ratio 2.4, 95% CI 1.2-4.9).
treatment results and prognostic/predictive factors
Overall, 327 patients suffered from tumor progression and 310 deceased during the follow-up period. Median progression-free survival (PFS) and median overall survival (OS) were 6.4 and 12.8 months, respectively. Outcome stratified for EOR when compared with biopsy, first-line treatment, and MGMT methylation status is given in Table 2 : outcome was best in case of RT plus CT (median PFS: 7.8 months/median OS: 17.1 months) and worst after supportive treatment (median PFS: 2.7 months/median OS: 3.0 months; supplementary Figure S1 , available at Annals of Oncology online). GTR was associated with superior OS (median: 17.1 
Cox models
One variable models are given in supplementary Table S1 , available at Annals of Oncology online. Multivariate Cox regression analyses of both the overall population and the subpopulation receiving RT plus CT revealed similar results: favorable prognostic factors for OS were age ≤60 years, KPS of ≥80, GTR, MGMT promoter methylation, and RT plus CT; incomplete resection was not better than biopsy (Table 3 ).
discussion
The highly invasive growth characteristics of glioblastomas explain that curative surgical treatment cannot be achieved [1] . Nevertheless, beneficial cytoreductive effects of GTR have been reported, which is defined as complete resection of the contrastenhancing tumor parts [6, 12, 13] . According to more recently published prospective randomized data, GTR can be expected to be achieved in 40% of glioblastoma patients [14] . The majority of glioblastoma patients still undergo incomplete resection and some of them receive biopsy only, which is due to diffuse tumor extension, affection of functional relevant areas, patient-related risk factors (such as increased age and co-morbidity), or any combination of these factors [9, 15] . Surprisingly, the prognostic impact of incomplete resection when compared with biopsy only remains unclear. The traditional view is that GTR is better than incomplete resection and the latter is better than biopsy [2, 16] . A few studies, however, that have addressed this issue did not analyze EOR by early postoperative MRI, did not control the effect of MGMT promoter methylation and applied treatment strategies, and/or were seriously biased due to the influence of other prognostic factors (in favor of the resection group) [16, 17] . The current prospective observational study, which analyzed outcome measurements of a large and unselected patient population collected in six academic centers with a dedicated focus on neurooncology, goes one step beyond these limitations: outcome measurements were adjusted for the effects of MGMT promoter methylation and other important patient-, tumor-, and treatment-related factors. Patients undergoing biopsy only were used as a reference group for the prognostic evaluation of open tumor resection. This approach overcomes a selection bias, which always occurs when comparing surgery responders (GTR) with nonresponders (incomplete resection) [18] . It was remarkable that the pretreatment prognostic profile of the biopsy and the incomplete resection groups was not as different as usually found [16, 17] : patients of the biopsy group were only slightly older, did not rate worse on the KPS scale, and did not exhibit higher frequencies of eloquent tumor locations than those undergoing incomplete resection. Hence, patients in these two groups were relatively well balanced. It was noteworthy, however, that biopsied patients were less likely to receive RT or RT plus CT in this series.
In accordance with other data, we found GTR to prolong OS [5, 6, 12, 16] . A prognostic impact of incomplete resection, however, could not be detected: incomplete resection did not provide advantages with respect to OS when compared with biopsy alone. This was demonstrated in both the full analysis and the subgroup analysis set of patients treated with RT plus CT. The latter analysis was carried out to account for the described treatment-related imbalances in the full analysis set: still existing but not significant differences in OS between biopsied and incompletely resected patients in the full analysis set resolved nearly completely in the subgroup analysis. Beyond RT plus CT, MGMT promoter methylation turned out to be the most powerful factor influencing OS. The outcome in biopsied and MGMT-methylated tumors was better than in tumors lacking MGMT promoter methylation after GTR and RT plus CT. The study results confirmed previously reported surprisingly long OS of biopsied glioblastoma patients after combined treatment in case of a methylated MGMT promoter [9] . Apparently, tumors' biology by far outweighs the prognostic impact of resective surgery. The prognostic models did not indicate interactions between the influence of EOR when compared with biopsy and MGMT promoter methylation status. Surgery was not more effective in unmethylated or methylated tumors.
EOR was dichotomized in the current report: those exhibiting any gadolinium enhanced volume on their early postoperative MRI were classified as incomplete resection. The chosen classification scheme is supported by the results of the post hoc evaluation of the prospective randomized data by Stummer et al. [6] : no distinct survival rates were found for subgroups undergoing different degrees of EOR; only those receiving GTR did significantly better. Since we considered these data as the currently most convincing ones for the prognostic evaluation of EOR, the current study protocol was designed accordingly.
Retrospective comparison of tumor size pre-and postoperatively has proposed a linear increase between EOR and survival beyond a threshold of ∼78% in one more recently published study [19] . The authors, however, have described overlapping subpopulations regarding EOR (>78%, >80%, >90% etc.), and it remains, therefore, unclear to which extent the applied top-down threshold calculation has been biased by those undergoing complete or nearly complete resection. Our data did not support those assumptions: for those undergoing RT plus CT, the prognostic impact of GTR was only moderate when compared with biopsy only. Thus, the existence of true prognostic relevant thresholds in addition to GTR seems to be unlikely. The provided prognostic models of this study rather indicate nonlinear correlations between EOR and outcome.
The proponents of linear correlations between EOR and outcome are confronted with so far unresolved methodological problems: a proper identification of thresholds in addition to GTR demands nonoverlapping subgroups exhibiting distinct degrees of EOR. Thus, large multi-institutional studies are necessary to analyze the interesting idea of a resection threshold for glioblastoma patients. Additionally, volumetric estimation of postsurgical MRI scans has been shown to suffer from low interobserver agreement [20, 21] .
Apparently, two different classes of glioblastoma patients exist: those harboring resectable tumors (which should be resected) and those harboring unresectable ones, which do not need partial 'debulking' unless decompressive surgery of pronounced and symptomatic space occupying lesions is necessary [22] . This conclusion is important for the patient and the treating oncologist: surgery-related complications of potentially superfluous incomplete resection might delay the initiation of adjuvant treatment, decrease quality of life, and comprise outcome [7, 15] . Even though in the current series, the complication rate after open tumor resection was in the lower range of reported data in the literature [15] , it was still 10 times higher than after biopsy.
We did not find any prognostic impact of open tumor resection on PFS. The estimation of PFS, however, might be biased in unfavor of the resection group, particularly in case of GTR, as usually the appearance of any new lesion after GTR is classified as tumor recurrence; in contrast, a 25% increase in tumor volume is required for indication of tumor progression after incomplete resection or biopsy [11] .
In summary, we found a moderate favorable prognostic effect of GTR in the era of RT plus CT. The efficacy of GTR was not influenced of MGMT promoter methylation, which turned out to be the most powerful pretreatment factor for OS and PFS. In contrast, the prognostic value of incomplete resection when compared with biopsy only remains questionable. The indication of biopsy should be reconsidered for unresectable tumors, as biopsy can be safely carried out and enabled adequate histological diagnosis and determination of the MGMT promoter methylation status even in patients, e.g. with eloquent tumors.
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